Journal
ONCOLOGY RESEARCH
Volume 27, Issue 4, Pages 503-508Publisher
COGNIZANT COMMUNICATION CORP
DOI: 10.3727/096504018X15344989701565
Keywords
Astragaloside IV (AS-IV); Non small cell lung cancer (NSCLC); Akt; GSK-3 beta; beta-Catenin
Categories
Funding
- Heilongjiang University of Chinese Medicine PhD Innovation Fund [2015bs05]
Ask authors/readers for more resources
Astragaloside IV (AS-IV) is an active ingredient in Astragalus membranaceus and is involved in various biological processes, such as regulating the immune system, and counteracting inflammation and malignancy. The aim of this study was to explore the effect of AS-IV on non-small cell lung cancer (NSCLC) cells. Cell counting kit (CCK)-8 assay and flow cytometry were performed to investigate cell survival and cell death, and Western blotting was performed to assess protein expression. We found that AS-IV inhibited the migration and proliferation of NSCLC cells and caused a noticeable increase in cell death. Furthermore, the expression of Bax, a marker of cell death, was increased, whereas the expression of Bcl-2, an antiapoptotic protein, was reduced. AS-IV also promoted cleavage of caspase-3, another indication of apoptosis. Finally, the Akt/GSK-3 beta/beta-catenin axis was suppressed in response to AS-IV. Taken together, these fmdings provide evidence that AS-IV inhibits NSCLC development via inhibition of the Akt/GSK-3 beta/beta-catenin signaling axis. We therefore propose that AS-IV represents a promising novel agent for the treatment of NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available